ATE166786T1 - Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis - Google Patents

Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis

Info

Publication number: ATE166786T1
Authority: AT; Austria
Prior art keywords: ulcerative; rapamycin; crohn; disease; treatment
Prior art date: 1992-08-17

Application number

AT93306248T

Other languages

English (en)

Inventor

Craig Eugene Caufield

John Henry Musser

Surendra Nath Sehgal

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-17

Filing date

1993-08-06

Publication date

1998-06-15

1993-08-06 Application filed by American Home Prod filed Critical American Home Prod

1998-06-15 Application granted granted Critical

1998-06-15 Publication of ATE166786T1 publication Critical patent/ATE166786T1/de

Links

206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
208000011231 Crohn disease Diseases 0.000 title abstract 2
206010036774 Proctitis Diseases 0.000 title abstract 2
206010036783 Proctitis ulcerative Diseases 0.000 title abstract 2
201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT93306248T 1992-08-17 1993-08-06 Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis ATE166786T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/931,243 US5286731A (en)	1991-09-17	1992-08-17	Method of treating immunoinflammatory bowel disease

Publications (1)

Publication Number	Publication Date
ATE166786T1 true ATE166786T1 (de)	1998-06-15

Family

ID=25460461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93306248T ATE166786T1 (de)	1992-08-17	1993-08-06	Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis

Country Status (12)

Country	Link
US (1)	US5286731A (de)
EP (1)	EP0583925B1 (de)
JP (1)	JP2637682B2 (de)
KR (1)	KR100299395B1 (de)
AT (1)	ATE166786T1 (de)
AU (1)	AU677011B2 (de)
CA (1)	CA2104042A1 (de)
DE (1)	DE69318902T2 (de)
DK (1)	DK0583925T3 (de)
ES (1)	ES2116415T3 (de)
GR (1)	GR3027610T3 (de)
SG (1)	SG47786A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5434260A (en) *	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
US5480988A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5489680A (en) *	1992-10-13	1996-02-06	American Home Products Corporation	Carbamates of rapamycin
US5480989A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US6204243B1 (en)	1993-09-01	2001-03-20	Novatis Ag	Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5389639A (en) *	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5525610A (en) *	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5463048A (en) *	1994-06-14	1995-10-31	American Home Products Corporation	Rapamycin amidino carbamates
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
US20040018236A1 (en) *	1995-05-08	2004-01-29	Robert Gurny	Nanoparticles for oral administration of pharmaceutical agents of low solubility
ATE340586T1 (de)	1996-07-30	2006-10-15	Novartis Pharma Gmbh	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
IT1289815B1 (it) *	1996-12-30	1998-10-16	Sorin Biomedica Cardio Spa	Stent per angioplastica e relativo procedimento di produzione
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
ATE411321T1 (de)	2000-09-19	2008-10-15	Wyeth Corp	Wasserlösliche rapamycin-ester
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
TWI286074B (en)	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CA2441007C (en) *	2001-03-15	2009-06-09	Enteron Pharmaceuticals, Inc.	Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin dialdehydes
WO2003018573A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin 29-enols
US6641611B2 (en)	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
ES2485841T3 (es)	2002-02-01	2014-08-14	Ariad Pharmaceuticals, Inc	Compuestos que contienen fósforo y usos de los mismos
RU2344821C2 (ru)	2002-07-30	2009-01-27	Уайт	Парентеральные композиции, содержащие гидроксиэфиры рапамицина
CN100415233C (zh) *	2002-09-17	2008-09-03	惠氏公司	口服制剂
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (de) *	2003-04-22	2007-01-24	Wyeth	Antineoplastische zusammensetzungen
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) *	2004-11-15	2006-12-19	Allergan, Inc.	Therapeutic methods using cyclosporine components
US20070185150A1 (en)	2005-11-14	2007-08-09	Bedrosian Camille L	Therapeutic methods
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
JP6049160B2 (ja)	2006-09-13	2016-12-27	エリクシアーメディカルコーポレイション	大環状ラクトン化合物およびその使用方法
US20100086579A1 (en) *	2008-10-03	2010-04-08	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
BRPI1010655A2 (pt)	2009-04-10	2019-09-03	Qi Haiyan	novos agentes antienvelhecimento e métodos para identificá-los
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US20110150856A1 (en) *	2009-12-21	2011-06-23	Sarah Bacus	Compositions and methods for treatment of vitiligo
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
CH677448A5 (de) *	1987-11-09	1991-05-31	Sandoz Ag
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5023264A (en) *	1990-07-16	1991-06-11	American Home Products Corporation	Rapamycin oximes
US5023263A (en) *	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
JP2675194B2 (ja) *	1990-08-10	1997-11-12	スミスクライン・ビーチャム・コーポレイション	免疫抑制組成物
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) *	1991-05-07	1992-04-07	American Home Products Corporation	Reduction products of rapamycin
US5138051A (en) *	1991-08-07	1992-08-11	American Home Products Corporation	Rapamycin analogs as immunosuppressants and antifungals
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease

1992
- 1992-08-17 US US07/931,243 patent/US5286731A/en not_active Expired - Lifetime
1993
- 1993-08-06 DK DK93306248T patent/DK0583925T3/da active
- 1993-08-06 EP EP93306248A patent/EP0583925B1/de not_active Expired - Lifetime
- 1993-08-06 DE DE69318902T patent/DE69318902T2/de not_active Expired - Fee Related
- 1993-08-06 SG SG1996004367A patent/SG47786A1/en unknown
- 1993-08-06 AT AT93306248T patent/ATE166786T1/de not_active IP Right Cessation
- 1993-08-06 ES ES93306248T patent/ES2116415T3/es not_active Expired - Lifetime
- 1993-08-13 CA CA002104042A patent/CA2104042A1/en not_active Abandoned
- 1993-08-13 KR KR1019930015662A patent/KR100299395B1/ko not_active Expired - Fee Related
- 1993-08-16 JP JP5202212A patent/JP2637682B2/ja not_active Expired - Fee Related
- 1993-08-16 AU AU44654/93A patent/AU677011B2/en not_active Ceased
1998
- 1998-08-07 GR GR980401788T patent/GR3027610T3/el unknown

Also Published As

Publication number	Publication date
DK0583925T3 (da)	1998-10-12
SG47786A1 (en)	1998-04-17
JPH06183967A (ja)	1994-07-05
AU4465493A (en)	1994-02-24
HK1009641A1 (en)	1999-06-04
JP2637682B2 (ja)	1997-08-06
DE69318902D1 (de)	1998-07-09
EP0583925A1 (de)	1994-02-23
EP0583925B1 (de)	1998-06-03
AU677011B2 (en)	1997-04-10
ES2116415T3 (es)	1998-07-16
DE69318902T2 (de)	1999-02-25
KR940003555A (ko)	1994-03-12
US5286731A (en)	1994-02-15
GR3027610T3 (en)	1998-11-30
KR100299395B1 (ko)	2001-10-22
CA2104042A1 (en)	1994-02-18

Legal Events

Date	Code	Title	Description
2007-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69318902D1 (de)	1998-07-09	Rapamycin zur Behandlung von Morbus Crohn, ulcerativer Colitis und ulcerative Proctitis
ATE135226T1 (de)	1996-03-15	Zusammensetzung enthaltend heparin und rapamycin
ATE187889T1 (de)	2000-01-15	Vorbeugung und behandlung der peripheren neuropathie
ATE148469T1 (de)	1997-02-15	Zyklosporine
DE69429369D1 (de)	2002-01-17	Verfahren und mittel zur behandlung abnormaler zustände des epitheliums von körperöffnungen
DE69734060D1 (de)	2005-09-29	Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
SG47639A1 (en)	1998-04-17	Method of treating hyperproliferative vascular disease
DE69435243D1 (de)	2009-11-19	Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE59508815D1 (de)	2000-12-07	Vorrichtung zum durchströmenden Behandeln von Textilgut od. Dgl.
NO903322L (no)	1991-01-29	Fremgangsmaate for behandling av huder og huder oppnaadd derved.
MX9205892A (es)	1993-04-01	Agentes colinergicos de oxima y amina de azabiciclo y metodos de tratamiento.
DE3582935D1 (de)	1991-07-04	Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DE59100861D1 (de)	1994-02-24	Kontinue-verfahren zur behandlung von textilen warenbahnen und entsprechende anlage.
FI944687A7 (fi)	1995-04-08	Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
SI1140119T1 (en)	2004-10-31	Use OF LOW MOLECULAR WEIGHT HEPARIN for the prevention and/or treatment of motoneuronal diseases
DE69321893D1 (de)	1998-12-10	Verfahren zum Nachweis von Alzheimer-Krankheit
DK0729360T3 (da)	2004-09-27	Lineære og cykliske peptider til behandling eller forebyggelse af Crohn's sygdom og /eller ulcerativ colitis
DE3585312D1 (de)	1992-03-12	Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69001988D1 (de)	1993-07-22	Behandlung des schocks mit cyclodextrin und dessen derivaten.
ATE316373T1 (de)	2006-02-15	Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
DE59509005D1 (de)	2001-03-08	Vorrichtung zum durchströmenden Behandeln von Textilgut od. dgl.
DE69126116D1 (de)	1997-06-19	Wirkstoff zur hepatitisverhütung und -behandlung
ATE81454T1 (de)	1992-10-15	Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.
DE3768595D1 (de)	1991-04-18	Einrichtung zur kontrolle und behandlung von gegenstaenden.